Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus.

Zhang J, Xian TZ, Teng Y, Wang X, Wu MX, Li C, Wang W, Man F, Zhang X, Wang X, Guo LX

International journal of clinical practice10 Oct 2022Cited by 2 (Europe PMC)

PMID37214201PMCIDPMC10199797DOI10.1155/2022/7128859PepBankPUB-37214201

Summary

BackgroundExenatide is a glucagon-like peptide-1 receptor agonist that can reduce body weight. This study aimed to determine the efficacy of exenatide on body mass index (BMI) reduction in patients with type 2 diabetes mellitus (T2DM) with differing baseline body weight, blood glucose, and atherosclerotic status and to determine if there is a correlation between BMI reduction and cardiometabolic indices in these patients.MethodsThis retrospective cohort study used data from our randomized controlled trial. A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included. The primary endpoint was a change in the BMI from the baseline to week 52. The secondary endpoint was a correlation between BMI reduction and cardiometabolic indices. Findings. The BMIs of overweight and obesity patients and those with glycated hemoglobin (HbA1c) ≥ 9% significantly decreased -1.42 ± 1.48 kg/m²(P=0.015) and -0.87 ± 0.93 kg/m²(P=0.003), respectively, at the baseline after 52 weeks of treatment. There was no reduction in BMI in patients with normal weight, HbA1c <9%, the nonatherosclerosis group, and the atherosclerosis group. The decrease in BMI was positively correlated with changes in blood glucose, high-sensitivity C-reactive protein (hsCRP), and systolic blood pressure (SBP).ConclusionBMI scores improved after exenatide treatment for 52 weeks in T2DM patients. Weight loss was affected by baseline body weight and blood glucose level. In addition, BMI reduction from the baseline to 52 weeks was positively correlated with baseline HbA1c, hsCRP, and SBP. Trial Registration. Chinese Clinical Trial Registry (ChiCTR-1800015658).

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In patients with T2DM and overweight or obesity, BMI decreased during exenatide/metformin treatment.
In plain wordsBMI decreased during exenatide plus metformin treatment in patients with diabetes and overweight or obesity.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBMI in overweight or obesity
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change
−1.42 kg/m2
overweight and obesity
Source sentences
Summary
The BMIs of overweight and obesity patients and those with glycated hemoglobin (HbA1c) ≥ 9% significantly decreased -1.42 ± 1.48 kg/m²(P=0.015) and -0.87 ± 0.93 kg/m²(P=0.003), respectively, at the baseline after 52 weeks of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used data from our randomized controlled trial.
Summary · context
A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3721420101
02HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In patients with T2DM and HbA1c ≥ 9%, BMI decreased during exenatide/metformin treatment.
In plain wordsBMI decreased during the combined treatment in patients with diabetes and higher starting blood sugar.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBMI with HbA1c at least 9%
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change
−0.87 kg/m2
HbA1c ≥ 9%
Source sentences
Summary
The BMIs of overweight and obesity patients and those with glycated hemoglobin (HbA1c) ≥ 9% significantly decreased -1.42 ± 1.48 kg/m²(P=0.015) and -0.87 ± 0.93 kg/m²(P=0.003), respectively, at the baseline after 52 weeks of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used data from our randomized controlled trial.
Summary · context
A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3721420102
03HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In normal-weight patients with T2DM, BMI did not decrease during exenatide/metformin treatment.
In plain wordsBMI did not decrease during the combined treatment in normal-weight patients with diabetes.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBMI in normal weight
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
There was no reduction in BMI in patients with normal weight, HbA1c <9%, the nonatherosclerosis group, and the atherosclerosis group.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used data from our randomized controlled trial.
Summary · context
A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3721420103
04HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In patients with T2DM and HbA1c <9%, BMI did not decrease during exenatide/metformin treatment.
In plain wordsBMI did not decrease during the combined treatment in patients with diabetes and lower starting blood sugar.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBMI with HbA1c below 9%
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
There was no reduction in BMI in patients with normal weight, HbA1c <9%, the nonatherosclerosis group, and the atherosclerosis group.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used data from our randomized controlled trial.
Summary · context
A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3721420104
05HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In patients with T2DM without atherosclerosis, BMI did not decrease during exenatide/metformin treatment.
In plain wordsBMI did not decrease during the combined treatment in patients with diabetes without atherosclerosis.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBMI without atherosclerosis
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
There was no reduction in BMI in patients with normal weight, HbA1c <9%, the nonatherosclerosis group, and the atherosclerosis group.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used data from our randomized controlled trial.
Summary · context
A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3721420105
06HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In patients with T2DM and atherosclerosis, BMI did not decrease during exenatide/metformin treatment.
In plain wordsBMI did not decrease during the combined treatment in patients with diabetes and atherosclerosis.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBMI with atherosclerosis
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
There was no reduction in BMI in patients with normal weight, HbA1c <9%, the nonatherosclerosis group, and the atherosclerosis group.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used data from our randomized controlled trial.
Summary · context
A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3721420106
07HumanNot a test of Exenatide (exendin-4) aloneObservational studyMechanism
In exenatide/metformin-treated patients with T2DM, BMI reduction correlated positively with changes in blood glucose.
In plain wordsDuring combined treatment, BMI reduction was linked to changes in blood glucose in patients with diabetes.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBMI change correlation with blood glucose change
Study
n = 27
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The decrease in BMI was positively correlated with changes in blood glucose, high-sensitivity C-reactive protein (hsCRP), and systolic blood pressure (SBP).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used data from our randomized controlled trial.
Summary · context
A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3721420107
08HumanNot a test of Exenatide (exendin-4) aloneObservational studyMechanism
In exenatide/metformin-treated patients with T2DM, BMI reduction correlated positively with changes in hsCRP.
In plain wordsDuring combined treatment, BMI reduction was linked to changes in an inflammation marker in patients with diabetes.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBMI change correlation with hsCRP change
Study
n = 27
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The decrease in BMI was positively correlated with changes in blood glucose, high-sensitivity C-reactive protein (hsCRP), and systolic blood pressure (SBP).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used data from our randomized controlled trial.
Summary · context
A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3721420108
09HumanNot a test of Exenatide (exendin-4) aloneObservational studyMechanism
In exenatide/metformin-treated patients with T2DM, BMI reduction correlated positively with changes in systolic blood pressure.
In plain wordsDuring combined treatment, BMI reduction was linked to changes in systolic blood pressure in patients with diabetes.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBMI change correlation with SBP change
Study
n = 27
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The decrease in BMI was positively correlated with changes in blood glucose, high-sensitivity C-reactive protein (hsCRP), and systolic blood pressure (SBP).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used data from our randomized controlled trial.
Summary · context
A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-3721420109

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.